Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands

References

• Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for chronic Obstructive Lung Disease (GOLD)2015 Available from: http://www.goldcopd.org/Accessed December 22, 2015
   Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020: global burden of disease studyLancet19973499064149815049167458
   PubMed Web of Science ®Google Scholar
• van GemertFKirengaBChavannesNPrevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational studyLancet Glob Health201531e44e5125539969
   PubMed Web of Science ®Google Scholar
• DalePRCerneckaHSchmidtMThe pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder diseaseCurr Opin Pharmacol201416314224682092
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroids in COPD: a controversyRespiration2010802899520501985
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00682922972099
   PubMed Web of Science ®Google Scholar
• van BovenJFde Jong-van den BergLTVegterSInhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysisDrug Saf201336423123623516006
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPUPLIFT investigatorsEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• HoogendoornMAlMJBeehKMCost-effectiveness of tiotropium versus salmeterol: the POET-COPD trialEur Respir J201341355656422700844
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat(R) in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SauerRHanselMBuhlRRubinRAFreyMGlaabTImpact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational studyInt J Chron Obstruct Pulmon Dis20161189189827217742
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• Selya-HammerCGonzalez-Rojas GuixNBaldwinMDevelopment of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in ItalyTher Adv Respir Dis Epub2016712
   Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• van BovenJFVegterSvan der MolenTPostmaMJCOPD in the working age population: the economic impact on both patients and governmentCOPD201310662963923845002
   PubMedGoogle Scholar
• GeijerRMTuutMKin’t VeenJCBroekhuizenBDChavannesNHSmeeleIJThe NHG guidelines “Adult asthma” and “COPD”Ned Tijdschr Geneeskd2015159A907625990339
   PubMedGoogle Scholar
• MiravitllesMGaldizJBHuertaAVillacampaACarcedoDGarcia-RioFCost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patientsInt J Chron Obstruct Pulmon Dis20161112313226848262
   PubMed Web of Science ®Google Scholar
• DonaldsonGCWedzichaJACOPD exacerbations. 1. EpidemiologyThorax200661216416816443707
   PubMed Web of Science ®Google Scholar
• TashkinDPLiNHalpinDAnnual rates of change in pre-vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPDRespir Med2013107121904191123972968
   PubMed Web of Science ®Google Scholar
• TashkinDPVariations in FEV(1) decline over time in chronic obstructive pulmonary disease and its implicationsCurr Opin Pulm Med201319211612423287286
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACalverleyPThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleRespir Res2013144023547660
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• van BovenJFTommeleinEBousseryKImproving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysisRespir Res2014156624929799
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMPOostenbrinkJBTashkinDPBurkhartDMonzBUDoes quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest200613041117112817035446
   PubMed Web of Science ®Google Scholar
• SpencerSJonesPWGLOBE Study GroupTime course of recovery of health status following an infective exacerbation of chronic bronchitisThorax200358758959312832673
   PubMed Web of Science ®Google Scholar
• PatersonCLanganCEMcKaigGAAssessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D)Qual Life Res20009552152711190007
   PubMed Web of Science ®Google Scholar
• Health Care Insurance BoardDutch Pharmacoeconomic Guidelines [in Dutch] Available from: http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2006/0604-guidelines-for-pharmacoeconomic-research/0604-guidelines-for-pharmacoeconomic-research/Guidelines+for+pharmacoeconomic+research.pdfAccessed July 24, 2015
   Google Scholar
• Costa-ScharplatzMStallbergBGoyalPAsukaiYGruenbergerJBPriceDCost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in SwedenAppl Health Econ Health Policy201513663764526324401
   PubMed Web of Science ®Google Scholar
• BriggsAHClaxtonKSculpherMJDecision Modelling for Health Economic EvaluationNew YorkOxford University Press2006
   Google Scholar
• Dutch National Health Compass Available from: http://www.natio-naalkompas.nl/object_binary/o20019_RP-COPD-2013.xls Accessed February 22, 2016
   Google Scholar
• MinasMHatzoglouCKaretsiECOPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry programPrim Care Respir J201019436337020532466
   PubMedGoogle Scholar
• HoogendoornMFeenstraTLSchermerTRHesselinkAERutten-van MolkenMPSeverity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practiceRespir Med20061001838615894477
   PubMed Web of Science ®Google Scholar
• Dutch medication adherence monitor Available from: http://www.therapietrouwmonitor.nl/cijfers/astmacopd-7Accessed January 26, 2016
   Google Scholar
• AtthobariJAsselbergsFWBoersmaCCost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)Clin Ther200628343244416750458
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• SuijkerbuijkAWde WitGAWijgaAHSocietal costs of asthma, COPD and respiratory allergyNed Tijdschr Geneeskd201315746A656224220178
   PubMedGoogle Scholar
• EkedahlAManssonNUnclaimed prescriptions after automated prescription transmittals to pharmaciesPharm World Sci2004261263115018256
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MolkenMPMonzBUFitzGeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health200581324615841892
   PubMed Web of Science ®Google Scholar
• PriceDGrayAGaleRCost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPDRespir Med2011105111635164721764277
   PubMed Web of Science ®Google Scholar
• PriceDAsukaiYAnanthapavanJMalcolmBRadwanAKeyzorIA UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource useAppl Health Econ Health Policy201311325927423529714
   PubMedGoogle Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
   PubMed Web of Science ®Google Scholar
• van BovenJFChavannesNHvan der MolenTRutten-van MolkenMPPostmaMJVegterSClinical and economic impact of non-adherence in COPD: a systematic reviewRespir Med2014108110311324070566
   PubMed Web of Science ®Google Scholar
• van der PalenJKleinJJvan HerwaardenCLZielhuisGASeydelERMultiple inhalers confuse asthma patientsEur Respir J19991451034103710596686
   PubMed Web of Science ®Google Scholar
• HettleRWoutersHAyresJCost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and BelgiumRespir Med2012106121722173323040833
   PubMed Web of Science ®Google Scholar